Assessment of CYP1A2 enzyme activity in relation to type-2 diabetes and habitual caffeine intake
Urry E, Jetter A, Landolt HP
Nutrition & metabolism · 30 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Case-control study (classified by our AI screen)
- Studied in
- People
- Main outcome
- Mechanisms only
Who paid for it
- Funding
- Independent funding
- Government
- National Science Foundation
- Government
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- University or hospital
- Universität Zürich
- Government
- Swiss National Science Foundation
- Grants
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (135414); Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030)
Based on 4 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2016-10-05 · Nutr Metab (Lond) · vol. 13 · issue 1 · p. 66
- Publisher
- BioMed Central
- Cited
- 66 citations · more than 92% of similar papers · 3.4× the field average
- Impact
- Top 10% most cited in its field
- References
- 34 works
- Access
- Open access (journal) · CC-BY
- Research areas
- Coffee research and impacts · Pharmacogenetics and Drug Metabolism · Carcinogens and Genotoxicity Assessment
- Keywords
- Paraxanthine, Caffeine, CYP1A2, Clinical nutrition, Type 2 diabetes, Population, Medicine, Diabetes mellitus, Endocrinology, Internal medicine, Metabolism, Cytochrome P450, Environmental health
3 authors
From CH
- Emily UrryZHAW Zurich University of Applied Sciences; University of Zurich
- Alexander JetterUniversity Hospital Zurich
- Hans‐Peter Landolt · correspondingZHAW Zurich University of Applied Sciences; University of Zurich
Abstract
Background
Coffee consumption is a known inducer of cytochrome P450 1A2 (CYP1A2) enzyme activity. We recently observed that a group of type-2 diabetes patients consumed more caffeine (coffee) on a daily basis than non-type-2 diabetes controls. Here, we investigated whether type-2 diabetes cases may metabolize caffeine faster than non-type-2 diabetes controls.
Methods
To estimate CYP1A2 enzyme activity, an established marker of caffeine metabolism, we quantified the paraxanthine/caffeine concentration ratio in saliva in 57 type-2 diabetes and 146 non-type-2 diabetes participants in a case-control field study. All participants completed validated questionnaires regarding demographic status, health and habitual caffeine intake, and were genotyped for the functional -163C > A polymorphism of the CYP1A2 gene.
Results
In the diabetes group, we found a larger proportion of participants with the highly inducible CYP1A2 genotype. Furthermore, the paraxanthine/caffeine ratio, time-corrected to mitigate the impact of different saliva sampling times with respect to the last caffeine intake, was higher than in the control group. Participants who reported habitually consuming more caffeine than the population average showed higher CYP1A2 activity than participants with lower than average caffeine consumption. Multiple regression analyses revealed that higher caffeine intake was potentially an important mediator of higher CYP1A2 activity.
Conclusions
Estimated CYP1A2 enzyme activity, and thus speed of caffeine metabolism, was higher in our type-2 diabetes group; this was possibly due to higher intake of caffeine, a known inducer of CYP1A2 enzyme activity. Given the fairly small sample sizes, the results need to be considered as preliminary and require validation in larger populations.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.